Seismic Therapeutic
Seismic Therapeutic is a biotech company using machine learning to develop biologics for autoimmune diseases, with a focus on novel enzyme and antibody therapeutics.
Company Overview
Seismic Therapeutic focuses on utilizing machine learning to discover new biologics for autoimmune disease treatment. With a mission to transform the treatment landscape for these diseases, the company integrates advanced technologies to create innovative therapeutics.
Immunology Pipeline
Seismic Therapeutic's pipeline includes novel enzyme and antibody therapeutics designed to target dysregulated adaptive immunity in autoimmune diseases. The lead programs feature a pan-IgG protease and Dual-cell Bidirectional antibodies, both aimed at addressing the root causes of autoimmune disorders.
Series B Financing
In a significant financial milestone, Seismic Therapeutic raised $121 million in Series B financing. This funding will be used to advance its cutting-edge immunology pipeline, allowing for further development and clinical trials of its promising drug candidates.
Technological Advancements
The IMPACT platform is central to Seismic Therapeutic's approach, integrating machine learning with structural biology and protein engineering. This advanced platform accelerates the generation of biologics, improving the speed and efficiency of drug development.
Industry Recognition
Seismic Therapeutic has received notable industry accolades, including being named an Endpoints 11 Most Promising Biotech Startup and Emerging Company of the Year in Life Sciences at the 2022 NEVY Awards. These recognitions underscore its potential impact on the biotech landscape.